Business Context and Reporting Period
This Form 6-K filing by GSK plc (a Foreign Private Issuer) reports a transaction in the company's own shares. The reporting period covers the month of July 2025, with the specific transaction date being July 1, 2025. The filing was signed on July 2, 2025.
Key Financial Metrics
The filing details a share repurchase transaction executed through Merrill Lynch International. Key metrics for the transaction on July 1, 2025, include:
- Shares Purchased: 484,326 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,384.00p; highest price paid was 1,414.50p.
- Average Price: Volume-weighted average price paid was 1,395.18p.
- Treasury Shares: Following this purchase, GSK holds 226,656,897 ordinary shares in treasury.
- Shares in Issue: 4,088,713,302 ordinary shares (excluding treasury shares).
- Voting Rights: Treasury shares represent 5.54% of total voting rights.
Material Changes
This transaction is part of an existing buyback programme. Since the commencement of the current non-discretionary agreement on June 4, 2025, the company has purchased an aggregate of 8,522,514 ordinary shares. The filing does not provide comparative financial data (revenue, profit, or cash flow) for prior periods as it is a transaction report rather than a financial statement.
Outlook and Management Commentary
The company confirms the purchase was effected pursuant to a non-discretionary agreement entered into with the broker on June 4, 2025. The purchased shares are held as Treasury shares. No specific guidance, risks, or unusual items regarding future operations are disclosed in this specific filing.
Investor Verification Checklist
- Verify the total number of treasury shares held (226,656,897) against the company's latest capital structure disclosures.
- Confirm the 5.54% voting rights attribution for treasury shares to ensure compliance with FCA Disclosure Guidance and Transparency Rules.
- Review the aggregate buyback volume since June 4, 2025 (8,522,514 shares) to assess the remaining capacity under the current programme.
- Note that the filing does not contain revenue, profit, or cash flow data; refer to the most recent Form 20-F or interim report for operational financials.